While shares of Halozyme (NASDAQ:HALO) rose earlier this month on news that BMO Capital Markets had tripled its price target on the stock, it has now fallen back down 15% on very similar, but opposite, news. Wedbush lowered Halozyme from outperform to neutral, and cut its price target a bit. Jefferies has taken an even harsher, more bearish, stance. In this video, Motley Fool health-care analyst David Williamson takes us through some of the drugs in Halozyme's pipeline that have analysts either so up or so down on the stock, and tells us that one of these two sides is going to be very wrong about this company.
David Williamson owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.